May 7, 2025 04:05PM
Mar 25, 2025 04:05PM
Mar 10, 2025 10:17PM
Mar 10, 2025 10:17PM
Feb 25, 2025 07:00AM
Feb 6, 2025 07:04AM
Feb 6, 2025 07:03AM 2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
Nov 12, 2024 07:00AM
Nov 4, 2024 04:01PM
Sep 25, 2024 06:13AM
Sep 25, 2024 06:00AM
Aug 29, 2024 07:00AM
Aug 7, 2024 07:00AM
Aug 5, 2024 07:00AM 2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
Jun 26, 2024 04:11PM
Jun 26, 2024 04:11PM
May 23, 2024 07:00AM
May 8, 2024 07:00AM
May 3, 2024 07:00AM
Apr 8, 2024 02:17PM
Apr 5, 2024 09:06AM U.S. FDA Approves Bristol Myers Squibb (BMY) and 2seventy bio’s (TSVT) Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Apr 5, 2024 09:05AM
Apr 1, 2024 07:31AM
Apr 1, 2024 07:30AM
Mar 20, 2024 05:04PM
Mar 20, 2024 05:04PM
Mar 15, 2024 06:27PM
Mar 15, 2024 04:59PM Bristol-Myers Squibb (BMY): FDA Advisers Vote 8:3 in Favor of Abecma as Earlier Treatment for a Type of Blood Cancer
Mar 5, 2024 07:00AM
Mar 1, 2024 07:00AM
Feb 27, 2024 08:05AM
Feb 27, 2024 08:00AM
Feb 5, 2024 04:05PM
Feb 5, 2024 07:02AM
Feb 5, 2024 06:59AM Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
Jan 30, 2024 07:03AM
Jan 30, 2024 07:02AM
Jan 30, 2024 07:01AM
Dec 12, 2023 03:22AM
Dec 11, 2023 07:30PM
Dec 11, 2023 07:17AM
Dec 11, 2023 07:00AM 2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
Dec 6, 2023 02:02PM
Dec 6, 2023 02:00PM
Nov 20, 2023 07:00AM
Nov 20, 2023 06:59AM
Nov 14, 2023 07:00AM
Nov 10, 2023 07:00AM
Sep 12, 2023 07:39AM 2seventy bio to lay off 40% of workforce; CEO to step down
Sep 12, 2023 07:02AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All